CorMedix
CRMD
92 hedge funds and large institutions have $66.2M invested in CorMedix in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 12 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 20
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
7% more funds holding
Funds holding: 86 → 92 (+6)
9.64% less ownership
Funds ownership: 42.28% → 32.64% (-9.6%)
13% less capital invested
Capital invested by funds: $76.1M → $66.2M (-$9.87M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
74% less call options, than puts
Call options by funds: $447K | Put options by funds: $1.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.73M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$911K |
| 3 |
Two Sigma Investments
New York
|
+$754K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$588K |
| 5 |
D.E. Shaw & Co
New York
|
+$537K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$4.38M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.38M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.09M |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$991K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
-$595K |
CRMD Hedge Fund Activity: Q3 2023 in Review
92 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2023, worth a combined $66.2M — down 13% from $76.1M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CRMD positions and 12 closed out — a net gain of 6 holders — while 34 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $1.73M. The largest seller was CVI Holdings, exiting entirely with an estimated $4.38M sold.
- 92 institutional investors held CorMedix (CRMD) as of Q3 2023, up from 86 in Q2 2023.
- Funds reported $66.2M of CorMedix stock for Q3 2023, down 13% quarter-over-quarter.
- 18 funds opened new CorMedix positions in Q3 2023 and 12 closed out, a net change of +6 holders.
- The largest CorMedix buyer in Q3 2023 was BlackRock, an estimated $1.73M added.
- The largest CorMedix seller in Q3 2023 was CVI Holdings, an estimated $4.38M sold.
Based on aggregated 13F filings for Q3 2023.